Recent studies have shown that LRIG1 function has a therapeutic potential for cancer and is also strongly related to EGFR signaling, as ectopic expression of LRIG1 reportedly inhibits oncogenic EGFR mutant EGFRvIII expression in glioblastoma [26] and the downstream MAPK and AKT signaling pathway in glioma [29]. This evidence concerns the gene EGFR and glioblastoma.